Our broad portfolio consists of multiplex panels that allow you to choose, within the panel, analytes that best meet your needs. On a separate tab you can choose the premixed cytokine format or a single plex kit.
Cell Signaling Kits & MAPmates™
Choose fixed kits that allow you to explore entire pathways or processes. Or design your own kits by choosing single plex MAPmates™, following the provided guidelines.
The following MAPmates™ should not be plexed together:
-MAPmates™ that require a different assay buffer
-Phospho-specific and total MAPmate™ pairs, e.g. total GSK3β and GSK3β (Ser 9)
-PanTyr and site-specific MAPmates™, e.g. Phospho-EGF Receptor and phospho-STAT1 (Tyr701)
-More than 1 phospho-MAPmate™ for a single target (Akt, STAT3)
-GAPDH and β-Tubulin cannot be plexed with kits or MAPmates™ containing panTyr
.
Catalog Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Select A Species, Panel Type, Kit or Sample Type
To begin designing your MILLIPLEX® MAP kit select a species, a panel type or kit of interest.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
If you have chosen panel analytes and then choose a premix or single plex kit, you will lose that customization.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Species
Panel Type
Selected Kit
Qty
Catalog Number
Ordering Description
Qty/Pack
List Price
96-Well Plate
Qty
Catalog Number
Ordering Description
Qty/Pack
List Price
Add Additional Reagents (Buffer and Detection Kit is required for use with MAPmates)
Qty
Catalog Number
Ordering Description
Qty/Pack
List Price
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Space Saver Option Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
This item has been added to favorites.
The Product Has Been Added To Your Cart
You can now customize another kit, choose a premixed kit, check out or close the ordering tool.
Billerica, Massachusetts: 10 January 2017 Sustainable Downstream Processing of Vaccines: The DiViNe Consortium (article published in EPM Magazine) Priyabrata Pattnaik, director, Worldwide Vaccine Initiative, MilliporeSigma talks about the need for downstream processing within vaccine production. Read article
Billerica, Massachusetts: 27 September 2016 MilliporeSigma's AFS Water Systems Reduce Water Consumption (article published in R&D Magazine) R&D Magazine features an R&D 100 Flashback, chosen from our R&D 100 archive of winners. This flashback is MilliporeSigma's AFS Water Systems, which won in 2015. Read article
Billerica, Massachusetts: 18 November 2015 The Making Of MilliporeSigma (article published in Chemical and Engineering News) On Nov. 18, Merck KGaA, Darmstadt, Germany, closed on the biggest acquisition in its 347-year history: The $17.0 billion purchase of the research-chemical supply house Sigma-Aldrich. Read article
Billerica, Massachusetts: 29 September 2015 EMD Millipore Accepts Silver Stevie® Award for AFS® E Water Purification Systems at the 2015 American Business Awards℠ EMD Millipore, the Life Science division of Merck KGaA, Darmstadt, Germany, accepted a Silver Stevie® Award for its AFS® E Water Purification Systems at a banquet held on Friday, September 11 in San Francisco. The award was conferred by The American Business Awards℠, the premier business awards program in the United States. Read article
China: 15 April 2015 Both pharmaceutical companies and their suppliers share an optimistic view on the Chinese biopharmaceutical market As China strengthens its legal system and pharmaceutical companies demand increasingly advanced technologies, EMD Millipore, a technology-based company that provides products and services for biopharmaceutical companies, sees big opportunities for expansion in the Chinese market. Read article
China: 13 April 2015 How do new biotechnologies promote the development of the pharmaceutical industry? Interview with Dr. Udit Batra, CEO and President of EMD Millipore In recent years, emerging biotechnologies covering areas as diverse as gene editing, next-generation genetic sequencing, and disposable biological products, have not only driven the rapid development of preclinical medicine, they have also created huge business opportunities for pharmaceutical companies, transforming the entire industry landscape. Read article
China: 08 April 2015 EMD Millipore tells media in Shanghai it seeks to improve its position in the Chinese market Recently, Dr. Udit Batra, CEO and President of EMD Millipore, and other executives from the company, attended EMD Millipore's media briefing in Shanghai. Dr. Udit Batra shared his views on the company's Chinese market development strategy, the recent acquisition of Sigma-Aldrich, and other issues with reporters. Read article
China: 08 April 2015 Further Expansion in the Chinese Market Interview with Dr. Udit Batra, CEO and President of EMD Millipore On March 31, 2015, Dr. Udit Batra, CEO and President, EMD Millipore was interviewed by three reporters including Process Industry, in Shanghai. Dr. Udit Batra introduced EMD Millipore's business profile and future plans, emphasizing that EMD Millipore will focus on growth in emerging markets, particularly China. In the interview, Dr. Udit Batra also shared details of EMD Millipore's philosophy and recent trends. Read article
China: 08 April 2015 GSK takes over Novartis' vaccines business amid large-scale integration of multinational pharmaceutical companies in China As China's macroeconomic slow-down is gradually accepted as the "new normal" trend, foreign pharmaceutical companies are suffering ever more problems arising from rapid expansion and excessive infrastructure investment in recent years. These companies are trying to adapt to the new normal by taking necessary measures in terms of compliance, mergers and acquisitions, personnel restructuring, and so on. Read article
China: 07 April 2015 Biotechnology Research & Development and the Chinese Market Oriental Morning Post: How did you benefit from the pharmaceutical industry acquisitions in China last year? Udit Batra: This has two benefits. One is to bring global products into China, and the second is to take Chinese products globally. EMD Millipore supports the processes both ways. Read article